The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Reply
Open accessAbstract
The effects of smoking on Corona Virus Disease 2019 (COVID-19) are currently unknown. The purpose of this study was to systematically examine the prevalence of current smoking among hospitalized patients with COVID-19 in China, considering the high-population smoking prevalence in China (26.6%). A systematic review of the literature (PubMed) was performed on April 1. Thirteen studies examining the clinical characteristics of hospitalized COVID-19 patients in China and presenting data on the smoking status were found. The pooled prevalence of current smoking from all studies was calculated by random-effect meta-analysis. To address the possibility that some smokers had quit shortly before hospitalization and were classified as former smokers on admission to the hospital, we performed a secondary analysis in which all former smokers were classified as current smokers. A total of 5960 patients were included in the studies identified. The current smoking prevalence ranged from 1.4% (95% CI 0.0-3.4%) to 12.6% (95% CI 10.6-14.6%). An unusually low prevalence of current smoking was observed from the pooled analysis (6.5%, 95% CI 4.9-8.2%) as compared to population smoking prevalence in China. The secondary analysis, classifying former smokers as current smokers, found a pooled estimate of 7.3% (95% CI 5.7-8.9%). In conclusion, an unexpectedly low prevalence of current smoking was observed among patients with COVID-19 in China, which was approximately 1/4th the population smoking prevalence. Although the generalized advice to quit smoking as a measure to reduce health risk remains valid, the findings, together with the well-established immunomodulatory effects of nicotine, suggest that pharmaceutical nicotine should be considered as a potential treatment option in COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1091 · Cited by 3,903 · cited 1×
“A literature search was conducted on PubMed, using the terms "(SARS-CoV-2 OR COVID-19 OR 2019-nCoV) AND Clinical" in the title or the abstract on April 1. Out of a total of 432 studies, 13 studies which included data about the smoking status were identified [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] […”
MethodA crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445 · cited 1×
“It has been observed that decreased ACE2 availability contributes to lung injury and ARDS development [9] [10] [11] .”
BackgroundNicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., et al. (2003) · Nature · doi:10.1038/nature01339 · Cited by 3,228 · cited 2×
“It inhibits the production of pro-inflammatory cytokines, such as TNF, IL-1, and IL-6, without inhibiting the production of anti-inflammatory cytokines, such as IL-10 [36, [40] [41] [42] .”
BackgroundZhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05985-9 · Cited by 2,684
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Physiology and immunology of the cholinergic antiinflammatory pathway
Tracey, K. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30555 · Cited by 1,563 · cited 1×
“Nicotine is an agonist of the cholinergic anti-inflammatory pathway that regulates host immune and inflammatory responses [36] [37] [38] [39] .”
BackgroundCholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis
Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Wang, H., Metz, C., Miller, E. J., et al. (2004) · Nature Medicine · doi:10.1038/nm1124 · Cited by 1,170
Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing
Wan, S., Xiang, Y., Fang, W., Zheng, Y., Li, B., Hu, Y., Lang, C., Huang, D., Sun, Q., Xiong, Y., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25783 · Cited by 982 · cited 1×
“A literature search was conducted on PubMed, using the terms "(SARS-CoV-2 OR COVID-19 OR 2019-nCoV) AND Clinical" in the title or the abstract on April 1. Out of a total of 432 studies, 13 studies which included data about the smoking status were identified [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] […”
MethodThe cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation
Pavlov, V. A., Wang, H., Czura, C. J., Friedman, S. G., & Tracey, K. J. (2003) · Molecular Medicine · doi:10.1007/bf03402177 · Cited by 772
Transdermal Nicotine for Active Ulcerative Colitis
Pullan, R. D., Rhodes, J., Ganesh, S., Mani, V., Morris, J. S., Williams, G. T., Newcombe, R. G., Russell, M., Feyerabend, C., Thomas, G., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403243301202 · Cited by 505 · cited 1×
“These products are relatively safe and have been administered therapeutically in non-smokers for neurological conditions and inflammatory bowel disease for longer periods than would be needed for COVID-19 [55] [56] [57] .”
Background
Cited by
Links between air pollution and COVID-19 in England
Travaglio, M., Yu, Y., Popovic, R., Selley, L., Leal, N. S., & Martins, L. M. (2021) · Environmental Pollution · doi:10.1016/j.envpol.2020.115859 · Cited by 633
Booth, A., Reed, A. B., Ponzo, S., Yassaee, A., Aral, M., Plans, D., Labrique, A., & Mohan, D. (2021) · PLOS ONE · doi:10.1371/journal.pone.0247461 · Cited by 551
The effect of smoking on COVID‐19 severity: A systematic review and meta‐analysis
Reddy, R. K., Charles, W. N., Sklavounos, A., Dutt, A., Seed, P. T., & Khajuria, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26389 · Cited by 458
Simons, D., Shahab, L., Brown, J., & Perski, O. (2021) · Addiction · doi:10.1111/add.15276 · Cited by 371
Dubey, M. J., Ghosh, R., Chatterjee, S., Biswas, P., Chatterjee, S., & Dubey, S. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.06.008 · Cited by 361
Metadata
- Authors
- Farsalinos, K., Barbouni, A., & Niaura, R.
- Venue
- Internal and Emergency Medicine
- Published
- 2020-09-21
- Volume
- 16
- Issue
- 1
- Pages
- 235-236
- ISSN
- 1828-0447 (ISSN-L)
- 1970-9366
- OpenAlex
- W3021685303
- Cited by
- 205
- References
- 13
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.